arrow
B

Brandon Hayes-Lattin

washington university (wustl)
H指数:42
被引数:6,656

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults

2026年ASH指南:青少年和年轻成人急性淋巴细胞白血病复发/难治性疾病的诊疗管理

2026-07-040
OA
Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome

早期神经系统反应预测anakinra治疗免疫效应细胞相关神经毒性综合征的结局

2026-06-020
OAAI
Real World Clinical Outcomes in Melanoma Patients Treated at a Single-Center Tumor Infiltrating Lymphocyte (TIL) Therapy Program using commercial Lifileucel.

单中心肿瘤浸润淋巴细胞(TIL)疗法项目使用商业化Lifileucel治疗黑色素瘤患者的真实世界临床结局

2026-04-250
PRE
Donor search and selection strategy to facilitate comparable transplant rates across donor search prognosis groups: A report from the BMT CTN 1702 trial

供者检索与选择策略以促进不同供者检索预后组间可比的移植率:BMT CTN 1702试验报告

2026-01-150
PRE
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial

基于供者搜索预后对同种异体细胞移植的准入:BMT CTN 1702试验

2025-11-080
PRE
PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

PTPN11基因突变与接受表观遗传药物(包括低甲基化剂和Venetoclax)治疗的急性髓系白血病患者生存期缩短相关。

BLOOD
IF23.1
2024-11-050
PRE
Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia

社会决定因素对急性髓系白血病患者获得造血干细胞移植的影响

BLOOD
IF23.1
2024-11-050
PRE
Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents plus Venetoclax in Newly Diagnosed AML

免疫表型标志物CD7和CD56可改善一线低甲基化药物联合Venetoclax在初诊AML中的风险分层

BLOOD
IF23.1
2024-11-050
PRE
NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

NCAM1 (CD56) 作为新诊断急性髓系白血病对标准强化诱导治疗的应答预测指标

BLOOD
IF23.1
2024-11-050
PRE
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis
2024-07-011
OAAI
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

新型冠状病毒肺炎对活跃的黑色素瘤治疗和有黑色素瘤病史的患者的影响

2023-03-232
OAAI
COVID-19 vaccination and breakthrough infections in patients with cancer

癌症患者的新型冠状病毒肺炎疫苗接种和突破性感染

2022-03-0180
OAAI